American Marconi Wireless News - Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025

Citi's 2025 Biopharma Back to School Summit; Boston, MA - September 2-3, 2025
Format: Fireside Chat
Day/Time: Wednesday, September 3 at 9:45 A.M. ET
Webcast: https://kvgo.com/2025-biopharma-back-to-school-conference/protagonist-therapeutics-inc-sep-2025

H.C. Wainwright 27th Annual Global Investment Conference; New York, NY - September 8-10, 2025
Format: Fireside Chat
Day/Time: Tuesday, September 9 at 11:30 A.M. ET
Webcast: https://journey.ct.events/view/2f5c929c-0a3b-473f-a149-bcc3e8c0ed5f

BofA 11^th Annual World Medical Innovation Forum; Boston, MA - September 15-17, 2025
Panel Title: Immunology: Creating the next blockbuster in I&I
Day/Time: Tuesday, September 16

If you are interested in meeting with the Protagonist team during the conferences, please reach out to your respective conference representative.

A replay of the presentations will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event.

About Protagonist

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application (NDA) for icotrokinra submitted to the FDA in July and the NDA submission for rusfertide is expected by end of 2025. Icotrokinra (formerly, JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") is licensed to J&J Innovative Medicines ("JNJ"), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for the development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]

Media Contact

Virginia Amann, Founder/CEO
+1 833 500 0061 ext 1
ENTENTE Network of Companies
[email protected]

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire

L.Harper--AMWN